| Niu, Junqi |
| Active, not recruiting | 4 | 640 | RoW | Tenofovir Amibufenamide（TMF）, HS-10234 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Hepatitis B, Chronic | 06/24 | 09/29 | | |
NCT06715319: Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis |
|
|
| Completed | 3 | 100 | RoW | OCA, Obeticholic Acid, UDCA, Placebo | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | PBC | 10/23 | 04/24 | | |
NCT04956328: Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC) |
|
|
| Recruiting | 3 | 120 | RoW | Obeticholic Acid Tablets, UDCA, Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Primary Biliary Cirrhosis | 09/23 | 09/23 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
| Active, not recruiting | 3 | 871 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
NCT05395416: Antaitavir Hasophate Capsules Combined With Yiqibuvir Tablets in Treatment Adult Patients With Chronic Hepatitis C |
|
|
| Recruiting | 2/3 | 520 | RoW | HEC74647PA+HEC110114, Antaitavir Hasophate+Yiqibuvir, Placebo | Sunshine Lake Pharma Co., Ltd. | Chronic HCV Infection | 04/23 | 04/23 | | |
NCT04278820: A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC) |
|
|
| Not yet recruiting | 2a | 130 | RoW | TQA3526, Placebo to match TQA3526 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Primary Biliary Cirrhosis | 11/22 | 11/22 | | |
NCT05484466: A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patients With CHB |
|
|
| Recruiting | 2a | 90 | RoW | ZM-H1505R, ZM-H1505R placebo, Baraclude | Shanghai Zhimeng Biopharma, Inc., Tigermed Consulting Co., Ltd | Hepatitis B, Chronic | 12/22 | 12/24 | | |
NCT04157257: An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy |
|
|
| Recruiting | 2 | 60 | RoW | TDF tablet, Tenofovir dipirofurate fumarate tablet, Entecavir Tablet, Entecavir, QL-007, QL-007 tablet | Qilu Pharmaceutical Co., Ltd. | Chronic Hepatitis b | 12/20 | 10/22 | | |
NCT04157699: An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b |
|
|
| Recruiting | 2 | 100 | RoW | TDF tablet, Tenofovir disoproxil fumarate tablet, QL-007 | Qilu Pharmaceutical Co., Ltd. | Chronic Hepatitis b | 12/20 | 10/22 | | |
NCT05734807: A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level Viremia |
|
|
| Completed | 2 | 74 | RoW | Nucleoside/nucleotide reverse transcriptase inhibitors (NrtIs), HH-003 and NrtIs, HH-003, NrtIs and PEG-IFN-α | Huahui Health | Chronic HBV Infection | 04/24 | 04/24 | | |
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection |
|
|
| Completed | 2 | 250 | RoW | GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table | Sunshine Lake Pharma Co., Ltd. | Chronic HBV Infection | 06/22 | 09/23 | | |
NCT05637541: Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets |
|
|
| Recruiting | 2 | 90 | RoW | GST-HG141 | Fujian Akeylink Biotechnology Co., Ltd. | Chronic Hepatitis b | 08/23 | 12/23 | | |
NCT05827146: Study of Hepalatide in Chronic Hepatitis D(CHD) Patients |
|
|
| Completed | 2 | 23 | RoW | Hepalatide, L47, Hepalatide Placebo, Placebo | Shanghai HEP Pharmaceutical Co., Ltd. | Chronic Hepatitis D Infection | 01/24 | 02/24 | | |
NCT05193916: A Phase II Clinical Trial of Chiglitazar for NASH |
|
|
| Completed | 2 | 104 | RoW | chiglitazar sodium tablets, Bilessglu®, CS-038, Carfloglitazar, Placebo, simulant of chiglitazar | Chipscreen Biosciences, Ltd. | NASH | 01/24 | 01/24 | | |
NCT06550128: Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Subjects With Chronic Hepatitis B (CHB). |
|
|
| Active, not recruiting | 2 | 60 | RoW | AHB-137 injection, Placebo | Ausper Biopharma Co., Ltd. | Hepatitis B, Chronic | 04/25 | 06/26 | | |
NCT05689645: F573 for Injection for the Treatment of Liver Injury/Failure |
|
|
| Recruiting | 2 | 97 | RoW | F573 for injection, Sterilizing water for injection | Beijing Continent Pharmaceutical Co, Ltd. | Acute Liver Failure, Acute-On-Chronic Liver Failure | 09/25 | 03/26 | | |
NCT06115993: A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepatitis B (CHB) Patients |
|
|
| Active, not recruiting | 1/2 | 270 | RoW | AHB-137 injection, Placebo | Ausper Biopharma Co., Ltd. | Hepatitis B, Chronic | 12/24 | 01/26 | | |
NCT06452693: A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B |
|
|
| Not yet recruiting | 1/2 | 162 | RoW | TQA3038 injection/placebo, Nucleotide drugs Control group | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatitis B, Chronic | 09/26 | 09/26 | | |
NCT04499443: Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of GST-HG131 Tablets |
|
|
| Recruiting | 1 | 124 | RoW | GST-HG131 tablets, Placebo | Fujian Cosunter Pharmaceutical Co. Ltd | Hepatitis B | 03/21 | 05/21 | | |
NCT05391360: Evaluation Freethiadine Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study |
|
|
| Completed | 1 | 128 | RoW | Freethiadine tablets(part I), Freethiadine tablets (part II), Freethiadine placebo tablets, entecavir tablets | Sunshine Lake Pharma Co., Ltd. | Hepatitis B, Chronic | 01/23 | 01/23 | | |
